BEGIN:VCALENDAR VERSION:2.0 PRODID:DPCALENDAR CALSCALE:GREGORIAN BEGIN:VTIMEZONE TZID:America/Los_Angeles X-MICROSOFT-CDO-TZID:13 BEGIN:STANDARD DTSTART:20251102T090000 TZOFFSETFROM:-0700 TZOFFSETTO:-0800 TZNAME:PST END:STANDARD BEGIN:STANDARD DTSTART:20261101T090000 TZOFFSETFROM:-0700 TZOFFSETTO:-0800 TZNAME:PST END:STANDARD BEGIN:DAYLIGHT DTSTART:20260308T100000 TZOFFSETFROM:-0800 TZOFFSETTO:-0700 TZNAME:PDT END:DAYLIGHT END:VTIMEZONE X-WR-TIMEZONE:America/Los_Angeles BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20160623T080000 DTEND;TZID=America/Los_Angeles:20160625T170000 UID:5A787B8D-4A66-4B44-B09D-D595AB9A8A0E SUMMARY:9th International Symposium on Focal Therapy and Imaging in Prostate and Kidney Cancer CREATED:20160120T162445Z DTSTAMP:20160120T162445Z URL:http://www.erasmusconferences.uk/microsites/1066 DESCRIPTION:Dear colleagues and friends,\NIn June 2016 it will have been nine years since the initiation of the first International Symposium on Focal Therapy and Imaging in Prostate and Kidney Cancer. We wish to return to the site of the inaugural meeting and host the 9th International Symposium on Focal Therapy and Imaging in Prostate and Kidney Cancer at the Washington Duke Inn Hotel in Durham, North Carolina, on June 23-25, 2016.\N\NMuch has transformed the landscape of prostate cancer over these last years. To start, there has been a growing recognition of the overtreatment of prostate cancer, with now a shift towards expectant management prior to consideration of radical whole gland therapy for select men with early stage prostate cancer. This understanding bodes well for focal therapy, as we have positioned it to be a minimally-invasive treatment that destroys the known area(s) of cancer while preserving a man's continence and potency. Today, there is growing interest in focal therapy for kidney and prostate cancers by physicians and patients alike.\NAt the recent 8th International Symposium held in the Netherlands we also witnessed the confidence and enthusiasm for incorporating real-time imaging into the diagnostic and treatment strategy for prostate and kidney cancer. In the coming year, we anticipate the continued exponential growth in new modalities and paradigms in the focal treatment of urogenital cancer.\NWe hope you will join us at the forefront of focal therapy in Durham in June 2016!\NThomas J. Polascik, MDProfessor of SurgeryDepartment of Surgery, Division of UrologyDuke University Medical CenterDurham, North Carolina, USA\N  X-ALT-DESC;FMTTYPE=text/html:

Dear colleagues and friends,

In June 2016 it will have been nine years since the initiation of the first International Symposium on Focal Therapy and Imaging in Prostate and Kidney Cancer. We wish to return to the site of the inaugural meeting and host the 9th International Symposium on Focal Therapy and Imaging in Prostate and Kidney Cancer at the Washington Duke Inn Hotel in Durham, North Carolina, on June 23-25, 2016.

Much has transformed the landscape of prostate cancer over these last years. To start, there has been a growing recognition of the overtreatment of prostate cancer, with now a shift towards expectant management prior to consideration of radical whole gland therapy for select men with early stage prostate cancer. This understanding bodes well for focal therapy, as we have positioned it to be a minimally-invasive treatment that destroys the known area(s) of cancer while preserving a man's continence and potency. Today, there is growing interest in focal therapy for kidney and prostate cancers by physicians and patients alike.

At the recent 8th International Symposium held in the Netherlands we also witnessed the confidence and enthusiasm for incorporating real-time imaging into the diagnostic and treatment strategy for prostate and kidney cancer. In the coming year, we anticipate the continued exponential growth in new modalities and paradigms in the focal treatment of urogenital cancer.

We hope you will join us at the forefront of focal therapy in Durham in June 2016!

Thomas J. Polascik, MD
Professor of Surgery
Department of Surgery, Division of Urology
Duke University Medical Center
Durham, North Carolina, USA

 

LAST-MODIFIED:20160330T034759Z SEQUENCE:6002594 LOCATION:Durham\, North Carolina 27705 GEO:36.02560900;-78.98538130 X-LOCATION-DISPLAYNAME:Washington Duke Inn Hotel X-ACCESS:1 X-HITS:1967 X-COLOR:3366CC X-SHOW-END-TIME:1 END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20160629T090000 DTEND;TZID=America/Los_Angeles:20160701T170000 UID:933C16A7-AC28-4F6E-BE0E-509266855B20 SUMMARY:Global Congress on Prostate Cancer 2016 CREATED:20160104T174238Z DTSTAMP:20160104T174238Z URL:http://ip43.ip-198-50-187.net/calendar-events/global-congress-on-prostate-cancer-2016.html DESCRIPTION:Welcome\NThe first three editions took place in Brussels (June 2012), Marseille (June 2013) and Rome (February 2015). More than 500 delegates and 35 leading experts in various fields of urology, radiology, radiotherapy and medical oncology discussed state-of-the art diagnosis and treatment of patients with various stages of prostate cancer. Reactions of experts, delegates and sponsors were unanimous: "Great value for money...Time really spent well...Thankful to be invited...What a faculty...Completely updated on PCa in 3 days...”.\NIt is therefore that we invite you to the fourth edition, which will take place from 29 June till 1 July 2016 in Vienna, Austria.\NJoin us\NThis fourth Global Congress on Prostate Cancer will continue to focus on topics which are actual and controversial, and which are of interest to all specialties dealing with prostate cancer. We will once again go in depth and beyond geographical and disciplinary boundaries, offering an exciting and fully up-to-date programme.\NAs this congress aims to be the major educational multidisciplinary event purely focusing on prostate cancer, we hope to attract up to 500 delegates from various specialties actively contributing to the discussion on how to deal with dilemmas when managing the disease.\NWe are very proud of the team of experts we have brought together. Their fabulous amount of expertise and different backgrounds will help us to create a high quality Congress.\NLet us all meet at the unique Liechtenstein Garden Palace.\NWe look forward sharing some exciting days with you.\NWelcome to Vienna!\NClick HERE to visit the conference website. X-ALT-DESC;FMTTYPE=text/html:

Welcome

The first three editions took place in Brussels (June 2012), Marseille (June 2013) and Rome (February 2015). More than 500 delegates and 35 leading experts in various fields of urology, radiology, radiotherapy and medical oncology discussed state-of-the art diagnosis and treatment of patients with various stages of prostate cancer. Reactions of experts, delegates and sponsors were unanimous: "Great value for money...Time really spent well...Thankful to be invited...What a faculty...Completely updated on PCa in 3 days...”.

It is therefore that we invite you to the fourth edition, which will take place from 29 June till 1 July 2016 in Vienna, Austria.

Join us

This fourth Global Congress on Prostate Cancer will continue to focus on topics which are actual and controversial, and which are of interest to all specialties dealing with prostate cancer. We will once again go in depth and beyond geographical and disciplinary boundaries, offering an exciting and fully up-to-date programme.

As this congress aims to be the major educational multidisciplinary event purely focusing on prostate cancer, we hope to attract up to 500 delegates from various specialties actively contributing to the discussion on how to deal with dilemmas when managing the disease.

We are very proud of the team of experts we have brought together. Their fabulous amount of expertise and different backgrounds will help us to create a high quality Congress.

Let us all meet at the unique Liechtenstein Garden Palace.

We look forward sharing some exciting days with you.

Welcome to Vienna!

Click HERE to visit the conference website.

LAST-MODIFIED:20160330T034850Z SEQUENCE:7380372 X-ACCESS:1 X-HITS:2525 X-COLOR:3366CC X-SHOW-END-TIME:1 END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20161208T070000 DTEND;TZID=America/Los_Angeles:20161209T160000 UID:EB17B45A-7DC4-4C73-B13E-08C2FDE51E32 SUMMARY:Practical Management Strategies and New Innovations in Prostate Radiotherapy CREATED:20160906T194628Z DTSTAMP:20160906T194628Z URL:https://mskcc.cloud-cme.com/aph.aspx?P=5&EID=37 DESCRIPTION:OverviewThe course will include coverage of the following topics:\N\NComparing outcomes for surgery and radiotherapy in clinically localized prostate cancer\NOptimal management strategies to treat acute and late side effects of radiotherapy\NTips for reducing errors and improving QA for prostate Brachytherapy\NUpdates on SBRT and Proton therapy in the treatment of prostate cancer\NSalvage radiotherapy after primary treatment failures and expected toxicity outcomes\NOptimal integration of hormonal therapy with prostate radiotherapy\NNew developments in External Beam Treatment Planning including MR-Treatment Planning\NGuidelines for the Radiation Oncologist contouring target and nodal regions\NIntegrating imaging into treatment selection and treatment\N\NCall for AbstractsParticipants are invited to submit an abstract for presentation at the meeting. Abstracts for the poster session will be selected on the basis of their scientific merit and content quality. The deadline for abstract submissions is 10/14/16. Please click on the Abstracts link above to learn more, or to submit an abstract.ObjectivesAt the conclusion of this activity participants will be able to:\NUnderstand the advantages and disadvantages of a radiotherapeutic approach compared to surgery in the treatment of clinically localized prostate cancer.\NTo provide information to the audience regarding optimal management of treatment related side effects after radiotherapy.\NTo familiarize the audience with new developments in treatment planning for EBRT and brachytherapy in the treatment of prostate cancer.\NTo highlight important advances in SBRT and Proton therapy in the treatment of prostate as well as discuss anticipated side effects of tumor control outcomes with these modalities.\NTo discuss the role of salvage radiotherapy after primary treatment failures and expected toxicity outcomes.\N X-ALT-DESC;FMTTYPE=text/html:MSKCC image

Overview

The course will include coverage of the following topics:



Call for Abstracts

Participants are invited to submit an abstract for presentation at the meeting. Abstracts for the poster session will be selected on the basis of their scientific merit and content quality. The deadline for abstract submissions is 10/14/16. Please click on the Abstracts link above to learn more, or to submit an abstract.

Objectives

At the conclusion of this activity participants will be able to:

  1. Understand the advantages and disadvantages of a radiotherapeutic approach compared to surgery in the treatment of clinically localized prostate cancer.
  2. To provide information to the audience regarding optimal management of treatment related side effects after radiotherapy.
  3. To familiarize the audience with new developments in treatment planning for EBRT and brachytherapy in the treatment of prostate cancer.
  4. To highlight important advances in SBRT and Proton therapy in the treatment of prostate as well as discuss anticipated side effects of tumor control outcomes with these modalities.
  5. To discuss the role of salvage radiotherapy after primary treatment failures and expected toxicity outcomes.
LAST-MODIFIED:20160906T195715Z SEQUENCE:647 LOCATION:417 E 68th St\, New York GEO:40.76490770;-73.95696160 X-LOCATION-DISPLAYNAME:Zuckerman Research Center X-ACCESS:1 X-HITS:2756 X-COLOR:3366CC X-SHOW-END-TIME:1 END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20170124T080000 DTEND;TZID=America/Los_Angeles:20170127T090000 UID:92C48DEE-9DF2-4CBD-ABB9-DA65BD0E4437 SUMMARY:27th International Prostate Cancer Update (IPCU 27) CREATED:20160330T025916Z DTSTAMP:20160330T025916Z URL:http://www.grandroundsinurology.com/ipcu/ DESCRIPTION:\NThe 27th Annual International Prostate Cancer Update (IPCU 27) will bring together leading experts from around the world to discuss the latest in diagnosis, treatment, and ongoing research in prostate cancer. The conference will contain lectures, debates, interactive discussions and multidisciplinary education programs. There is a need for medical oncologists, radiation oncologists, urologists, pharmacists, and nurses to understand the rationale behind targeted therapy for the treatment of localized and advanced prostate cancer.\NThis activity seeks to educate urologists and other healthcare professionals about the latest advances in the prevention, screening, and treatment of PCa. The International Prostate Cancer Update (IPCU) educational planning committee has identified the following educational gaps between recent research in prostate cancer and its integration into professional practice at the international, national, and community levels:\N• Prostate cancer diagnosis and treatment for the primary care physician• Current best practices in prevention of and screening for prostate cancer• Updates on the use of various biomarkers• Promising therapies, issues, and economic concerns in the treatment of localized disease• The sequencing and combinations of available therapies in 2017• Emerging treatment options for localized, advanced, and castration-resistant prostate cancer\N  X-ALT-DESC;FMTTYPE=text/html:

Screen Shot 2016 03 29 at 9.54.15 PM

The 27th Annual International Prostate Cancer Update (IPCU 27) will bring together leading experts from around the world to discuss the latest in diagnosis, treatment, and ongoing research in prostate cancer. The conference will contain lectures, debates, interactive discussions and multidisciplinary education programs. There is a need for medical oncologists, radiation oncologists, urologists, pharmacists, and nurses to understand the rationale behind targeted therapy for the treatment of localized and advanced prostate cancer.

This activity seeks to educate urologists and other healthcare professionals about the latest advances in the prevention, screening, and treatment of PCa. The International Prostate Cancer Update (IPCU) educational planning committee has identified the following educational gaps between recent research in prostate cancer and its integration into professional practice at the international, national, and community levels:

• Prostate cancer diagnosis and treatment for the primary care physician
• Current best practices in prevention of and screening for prostate cancer
• Updates on the use of various biomarkers
• Promising therapies, issues, and economic concerns in the treatment of localized disease
• The sequencing and combinations of available therapies in 2017
• Emerging treatment options for localized, advanced, and castration-resistant prostate cancer

 

LAST-MODIFIED:20160330T030620Z SEQUENCE:424 X-ACCESS:1 X-HITS:5712 X-COLOR:3366CC X-SHOW-END-TIME:1 END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20170309 DTEND;VALUE=DATE:20170312 UID:780ED800-A3F0-4740-B9AB-F02C7C0A31CB SUMMARY:Advanced Prostate Cancer Consensus Conference (APCCC) St. Gallen CREATED:20160303T205535Z DTSTAMP:20160303T205535Z URL:http://prostatecancerconsensus.org DESCRIPTION:In advanced prostate cancer, rapid and successful drug development has resulted in multiple treatment options, requiring careful decision making for individual patients. Clinicians face the increasingly difficult task of choosing from multiple potentially effective treatments that are also costly and potentially toxic.The inaugural Advanced Prostate Cancer Consensus Conference (APCCC) did provide a forum for discussion and debates on current treatment options for men with advanced prostate cancer. The conference concluded with voting by the panel on pre-defined consensus questions, targeting areas of primary clinical relevance. Following the conference a manuscript with containing the expert recommendations was published at Annals of Oncology.\NClick below to view:Scientific ProgramRegistration X-ALT-DESC;FMTTYPE=text/html:

StGallen image


In advanced prostate cancer, rapid and successful drug development has resulted in multiple treatment options, requiring careful decision making for individual patients. Clinicians face the increasingly difficult task of choosing from multiple potentially effective treatments that are also costly and potentially toxic.

The inaugural Advanced Prostate Cancer Consensus Conference (APCCC) did provide a forum for discussion and debates on current treatment options for men with advanced prostate cancer. The conference concluded with voting by the panel on pre-defined consensus questions, targeting areas of primary clinical relevance. Following the conference a manuscript with containing the expert recommendations was published at Annals of Oncology.

Click below to view:

Scientific Program

Registration

LAST-MODIFIED:20170123T200815Z SEQUENCE:28163560 LOCATION:St.Gallen GEO:47.42448180;9.37671730 X-LOCATION-DISPLAYNAME:St.Gallen, Switzerland X-ACCESS:1 X-HITS:4376 X-COLOR:3366CC X-SHOW-END-TIME:1 END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20170309T080000 DTEND;TZID=America/Los_Angeles:20170311T180000 UID:DC15613D-627B-41CC-ADA9-3967393AB94A SUMMARY:Advanced Prostate Cancer Consensus Conference (APCCC) 2017 CREATED:20160330T032743Z DTSTAMP:20160330T032743Z URL:http://www.apccc.org DESCRIPTION:\NDear Colleagues,\NWe are pleased to announce, that the registration for the next Advanced Prostate Cancer Consensus Conference (APCCC): 9-11th of March 2017 in St.Gallen Switzerland will open on Monday 4th of April 2016.\NA fantastic international expert panel has been confirmed and a draft of the scientific program is on our website available: www.apccc.org\NPlease note that due to high demand APCCC 2015 was completely sold out. In order to preserve the unique atmosphere the scientific committee decided to keep the location. If we have the same high demand in 2017 and in order to accommodate more participants, we will have this time a hall on site (not a gallery) with direct video transmission. This would mean that there is no guarantee for all participants to always get a seat in the main room but we want to enable as many participants as possible to attend the exciting conference.\NPlease share this email with your friend and colleagues that also might be interested in attending in 2017.\NWe look forward to seeing you next year in beautiful St.Gallen!\NAurelius Omlin and Silke GillessenOn behalf of the Scientific Committee X-ALT-DESC;FMTTYPE=text/html:

image006

Dear Colleagues,

We are pleased to announce, that the registration for the next Advanced Prostate Cancer Consensus Conference (APCCC): 9-11th of March 2017 in St.Gallen Switzerland will open on Monday 4th of April 2016.

A fantastic international expert panel has been confirmed and a draft of the scientific program is on our website available: www.apccc.org

Please note that due to high demand APCCC 2015 was completely sold out. In order to preserve the unique atmosphere the scientific committee decided to keep the location. If we have the same high demand in 2017 and in order to accommodate more participants, we will have this time a hall on site (not a gallery) with direct video transmission. This would mean that there is no guarantee for all participants to always get a seat in the main room but we want to enable as many participants as possible to attend the exciting conference.

Please share this email with your friend and colleagues that also might be interested in attending in 2017.

We look forward to seeing you next year in beautiful St.Gallen!

Aurelius Omlin and Silke Gillessen
On behalf of the Scientific Committee

LAST-MODIFIED:20160330T034541Z SEQUENCE:1078 X-ACCESS:1 X-HITS:5090 X-COLOR:3366CC X-SHOW-END-TIME:1 END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20170316T080000 DTEND;TZID=America/Los_Angeles:20170319T170000 UID:F4AF7BEF-FD34-4D50-9417-DAC7756119D9 SUMMARY:The 22nd Annual Scottsdale Prostate Cancer Symposium 2017 CREATED:20170116T185351Z DTSTAMP:20170116T185351Z URL:http://www.grandroundsinurology.com/spcs/ DESCRIPTION:Program OverviewWorld-renowned experts in the management of prostate cancer will provide a technical update on all aspects of diagnosis and treatment of localized and advanced disease.Topics of discussion will include Genetic Markers, Prostate Pathology, mpMRI, Mapping Biopsy, Active Surveillance, Focal Therapy, Robotic Prostatectomy, Cryoablation, HIFU, Brachytherapy, IMRT/IGRT, New Approaches to Castrate Resistant Disease, Micronutrients, Morbidity Management and Testosterone Replacement Therapy.This program aims to maximize the educational component and allow for time to explore all that the beautiful Scottsdale area offers in the spring.Target AudienceThis course is intended for urologists, radiation oncologists, medical oncologists, physicists, and other health care professionals. It will educate the attendees about advances in management of localized and advanced prostate cancer.AccreditationThe organizers have applied for AMA PRA Category 1 Credits™. X-ALT-DESC;FMTTYPE=text/html:Screen Shot 2017 01 16 at 12.51.47 PM


Program Overview

World-renowned experts in the management of prostate cancer will provide a technical update on all aspects of diagnosis and treatment of localized and advanced disease.
Topics of discussion will include Genetic Markers, Prostate Pathology, mpMRI, Mapping Biopsy, Active Surveillance, Focal Therapy, Robotic Prostatectomy, Cryoablation, HIFU, Brachytherapy, IMRT/IGRT, New Approaches to Castrate Resistant Disease, Micronutrients, Morbidity Management and Testosterone Replacement Therapy.
This program aims to maximize the educational component and allow for time to explore all that the beautiful Scottsdale area offers in the spring.


Target Audience

This course is intended for urologists, radiation oncologists, medical oncologists, physicists, and other health care professionals. It will educate the attendees about advances in management of localized and advanced prostate cancer.


Accreditation
The organizers have applied for AMA PRA Category 1 Credits™. LAST-MODIFIED:20170116T190750Z SEQUENCE:839 LOCATION:Scottsdale GEO:33.49417040;-111.92605190 X-LOCATION-DISPLAYNAME:Scottsdale, AZ X-ACCESS:1 X-HITS:2364 X-COLOR:3366CC X-SHOW-END-TIME:1 END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20170915 DTEND;VALUE=DATE:20170917 UID:13155650-ADE1-46E2-B7DA-D5786B89E475 SUMMARY:EAU Update on Prostate Cancer CREATED:20170814T163029Z DTSTAMP:20170814T163029Z URL:http://pca17.uroweb.org DESCRIPTION:Dear Friends and Colleagues,For the first time, a fully interactive, expert-led educational meeting focused on prostate cancer (PCa) management will take place in Vienna, Austria, from 15 to 16 September, marking the first of a series that is unique in the EAU’s programme on uro-oncology.With the goal to provide an in-depth and critical assessment of standard, innovative and prospective PCa therapies, the EAU has pooled the expertise of prostate cancer specialists from various European countries and faculty members of the European School of Urology (ESU) to organize the two-day programme that will cover pertinent topics in PCa management.Actual perspectives, practical approaches and insights into various treatment options will characterize the meeting that will challenge participants’ knowledge on guidelines, diagnosis, management issues, clinical dilemmas and surgical proficiency. Medical strategies will be thoroughly examined with to-the-point and incisive recommendations on systemic treatments, castration-resistant disease, drug selection or sequencing and complications management.Collaborating with the ESU, testing modules will be offered, and webinars and other training activities will hone and assess diagnostic and surgical skills. Using evidence-based medicine and interactive breakout sessions, difficulties in diagnosis, use of imaging tools, and follow-up strategies will be explored. A rotating faculty format will lead case discussions and the focused sessions will trigger a deeper inquiry into controversial issues in active surveillance, local salvage therapy and managing recurrent disease, among other topics.PCa17 is a compact meeting organized to fulfil educational goals and is the first of a series that will in the future also include renal, bladder and other malignant urological diseases. PCa17 distinguishes itself from other EAU meetings by its three-pronged scheme: interactive, practical and wide-ranging.Join us in Vienna! X-ALT-DESC;FMTTYPE=text/html:Screen Shot 2017 08 14 at 11.28.39 AM

Dear Friends and Colleagues,
For the first time, a fully interactive, expert-led educational meeting focused on prostate cancer (PCa) management will take place in Vienna, Austria, from 15 to 16 September, marking the first of a series that is unique in the EAU’s programme on uro-oncology.

With the goal to provide an in-depth and critical assessment of standard, innovative and prospective PCa therapies, the EAU has pooled the expertise of prostate cancer specialists from various European countries and faculty members of the European School of Urology (ESU) to organize the two-day programme that will cover pertinent topics in PCa management.

Actual perspectives, practical approaches and insights into various treatment options will characterize the meeting that will challenge participants’ knowledge on guidelines, diagnosis, management issues, clinical dilemmas and surgical proficiency. Medical strategies will be thoroughly examined with to-the-point and incisive recommendations on systemic treatments, castration-resistant disease, drug selection or sequencing and complications management.

Collaborating with the ESU, testing modules will be offered, and webinars and other training activities will hone and assess diagnostic and surgical skills. Using evidence-based medicine and interactive breakout sessions, difficulties in diagnosis, use of imaging tools, and follow-up strategies will be explored. A rotating faculty format will lead case discussions and the focused sessions will trigger a deeper inquiry into controversial issues in active surveillance, local salvage therapy and managing recurrent disease, among other topics.

PCa17 is a compact meeting organized to fulfil educational goals and is the first of a series that will in the future also include renal, bladder and other malignant urological diseases. PCa17 distinguishes itself from other EAU meetings by its three-pronged scheme: interactive, practical and wide-ranging.

Join us in Vienna! LAST-MODIFIED:20170814T164009Z SEQUENCE:580 X-ACCESS:1 X-HITS:827 X-COLOR:3366CC X-SHOW-END-TIME:1 END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20171017 DTEND;VALUE=DATE:20171018 UID:E4B0BC2C-AD7E-4447-9C7F-451C61BEE7A0 SUMMARY:State of the Art Imaging in the Diagnosis and Management of Prostate Cancer CREATED:20170821T193409Z DTSTAMP:20170821T193409Z URL:http://cmeregistration.hms.harvard.edu/events/state-of-the-art-imaging-in-the-diagnosis-and-management-of-prostate-cancer/event-summary-6f91c96c476a4ffdb5e380febafc51f7.aspx DESCRIPTION:Staying abreast of the rapidly advancing field of prostate imaging is paramount to the successful staging and treatment of patients with prostate cancer. This one-day CME course, State of the Art Imaging in the Diagnosis and Management of Prostate Cancer, will discuss current and new developments in multiparametric MRI (mpMRI) scanning techniques, MRI-ultrasound fusion biopsy, and other recent advances in imaging technology for advanced and recurrent prostate cancer. The course is designed to provide a focused, yet comprehensive advanced clinical review for practicing radiologists, medical oncologists, and radiation urologists. Participant learning and interaction will be encouraged through case reviews, question and answer sessions, and interaction with the course faculty. X-ALT-DESC;FMTTYPE=text/html:Screen Shot 2017 08 21 at 2.56.56 PM


Staying abreast of the rapidly advancing field of prostate imaging is paramount to the successful staging and treatment of patients with prostate cancer. This one-day CME course, State of the Art Imaging in the Diagnosis and Management of Prostate Cancer, will discuss current and new developments in multiparametric MRI (mpMRI) scanning techniques, MRI-ultrasound fusion biopsy, and other recent advances in imaging technology for advanced and recurrent prostate cancer. The course is designed to provide a focused, yet comprehensive advanced clinical review for practicing radiologists, medical oncologists, and radiation urologists. Participant learning and interaction will be encouraged through case reviews, question and answer sessions, and interaction with the course faculty. LAST-MODIFIED:20170821T195813Z SEQUENCE:1444 X-ACCESS:1 X-HITS:1143 X-COLOR:3366CC X-SHOW-END-TIME:1 END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20181026 DTEND;VALUE=DATE:20181030 UID:9ED2A5E0-CA33-49A4-8817-404985BB435C SUMMARY:The 25th Annual Prostate Cancer Foundation Scientific Retreat CREATED:20180601T221732Z DTSTAMP:20180601T221732Z URL:https://www.pcf.org/c/25th-annual-scientific-retreat/ DESCRIPTION:The 25th Annual Prostate Cancer Foundation Scientific Retreat will be held from October 26-28, 2018 (Friday thru Sunday), at the La Costa Resort in Carlsbad, CA.PCF Young Investigator Day will be held on October 25th 2018 for 2014-2018 PCF Young Investigators.The 3rd Annual PCF Women’s Networking Forum meeting and luncheon will be held the morning of October 26, 2018. All interested Retreat attendees are welcome to attend. RSVP will be required on the registration form.This event is the foremost scientific conference in the world on the biology and treatment of prostate cancer. The diversity, novelty, and extremely high impact of the topics presented as well as the diversity and excellence of the invited attendees make this a unique conference. The PCF Scientific Retreat reflects the unyielding commitment of PCF to ending death and suffering from prostate cancer. This investment by PCF fosters a collaborative culture unparalleled in any other cancer research area and has accelerated the understanding of prostate cancer biology and the treatment landscape.Attendance at the PCF Scientific Retreat is by invitation only. X-ALT-DESC;FMTTYPE=text/html:25TH PCFS

The 25th Annual Prostate Cancer Foundation Scientific Retreat will be held from October 26-28, 2018 (Friday thru Sunday), at the La Costa Resort in Carlsbad, CA.

PCF Young Investigator Day will be held on October 25th 2018 for 2014-2018 PCF Young Investigators.

The 3rd Annual PCF Women’s Networking Forum meeting and luncheon will be held the morning of October 26, 2018. All interested Retreat attendees are welcome to attend. RSVP will be required on the registration form.

This event is the foremost scientific conference in the world on the biology and treatment of prostate cancer. The diversity, novelty, and extremely high impact of the topics presented as well as the diversity and excellence of the invited attendees make this a unique conference. The PCF Scientific Retreat reflects the unyielding commitment of PCF to ending death and suffering from prostate cancer. This investment by PCF fosters a collaborative culture unparalleled in any other cancer research area and has accelerated the understanding of prostate cancer biology and the treatment landscape.

Attendance at the PCF Scientific Retreat is by invitation only. LAST-MODIFIED:20180601T221815Z SEQUENCE:43 X-ACCESS:1 X-HITS:2079 X-COLOR:3366CC X-SHOW-END-TIME:1 END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20181027 DTEND;VALUE=DATE:20181103 UID:03D4FB82-6DDD-4595-BE88-71A282F76873 SUMMARY:Asia-Pacific Prostate Society 8th Annual Conference 2018 CREATED:20180713T184239Z DTSTAMP:20180713T184239Z URL:http://apps2018.org/ DESCRIPTION:On behalf of President Bannakij Lojanapiwat, Vice-president Ji Youl Lee and Secretary General Jun Hyuk Hong, of the Asian Pacific Prostate Society (APPS),I would like to invite you to the 8th Congress of the Asian Pacific Prostate Society (APPS 2018 Maui) meeting In Wailea, Maui, USA.This will be held in conjunction with the 94th annual meeting of the Western Section of the American Urological Association (WSAUA Maui 2018) at the Grand Wailea Hotel, Maui.The APPS 2018 Maui meeting will be from Oct 27 to Oct 29, 2018, while the WSAUA Maui 2018 will run from Oct 28 to Nov 2, 2018. A joint session with the WSAUA is planned for Monday, Oct 29, 2018. Excellent presentations, speakers, and e-poster presentations are planned. There will be ample opportunity to interact with the WSAUA members, WSAUA meeting, and Exhibitors. Dress will be casual - no suits or ties please. Aloha or recreational attire is appropriate and expected.The on-line registration for the APPS 2018 Maui meeting will be processed by the APPS in Seoul, Korea. For those APPS registrants who wish to attend additional days of the WSAUA Maui 2018 meeting, after the APPS meeting ends, onsite registration for additional days will be available. Tickets for social events will be available for purchase onsite at the WSAUA registration desk. Please indicate your intent to purchase any social event tickets, particularly the Welcoming Reception on Sunday, Oct 28, 2018, on your APPS registration.Special meeting rates for the Grand Wailea Maui will be available online through the APPS website link for Hotel reservations. Please reserve your Hotel room as soon as possible, as the rooms go quickly.The Grand Wailea Hotel is a beautiful resort property; a wonderful stay can be enjoyed without leaving the resort. Maui has easily accessible beautiful beaches, great golf courses, and spectacular scenery for your enjoyment, as well.We look forward to seeing you on Maui in October!Robert G. Carlile, MDChairman of APPS2018 X-ALT-DESC;FMTTYPE=text/html:Screen Shot 2018 07 13 at 1.38.34 PM

On behalf of President Bannakij Lojanapiwat, Vice-president Ji Youl Lee and Secretary General Jun Hyuk Hong, of the Asian Pacific Prostate Society (APPS),
I would like to invite you to the 8th Congress of the Asian Pacific Prostate Society (APPS 2018 Maui) meeting In Wailea, Maui, USA.

This will be held in conjunction with the 94th annual meeting of the Western Section of the American Urological Association (WSAUA Maui 2018) at the Grand Wailea Hotel, Maui.

The APPS 2018 Maui meeting will be from Oct 27 to Oct 29, 2018, while the WSAUA Maui 2018 will run from Oct 28 to Nov 2, 2018. A joint session with the WSAUA is planned for Monday, Oct 29, 2018. Excellent presentations, speakers, and e-poster presentations are planned. There will be ample opportunity to interact with the WSAUA members, WSAUA meeting, and Exhibitors. Dress will be casual - no suits or ties please. Aloha or recreational attire is appropriate and expected.

The on-line registration for the APPS 2018 Maui meeting will be processed by the APPS in Seoul, Korea. For those APPS registrants who wish to attend additional days of the WSAUA Maui 2018 meeting, after the APPS meeting ends, onsite registration for additional days will be available. Tickets for social events will be available for purchase onsite at the WSAUA registration desk. Please indicate your intent to purchase any social event tickets, particularly the Welcoming Reception on Sunday, Oct 28, 2018, on your APPS registration.

Special meeting rates for the Grand Wailea Maui will be available online through the APPS website link for Hotel reservations. Please reserve your Hotel room as soon as possible, as the rooms go quickly.

The Grand Wailea Hotel is a beautiful resort property; a wonderful stay can be enjoyed without leaving the resort. Maui has easily accessible beautiful beaches, great golf courses, and spectacular scenery for your enjoyment, as well.

We look forward to seeing you on Maui in October!

Robert G. Carlile, MD
Chairman of APPS2018 LAST-MODIFIED:20180713T194607Z SEQUENCE:3808 X-ACCESS:1 X-HITS:1585 X-COLOR:3366CC X-SHOW-END-TIME:1 END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20190124 DTEND;VALUE=DATE:20190128 UID:3B08FADA-7A1E-49B6-B06D-DF1CD6ED57C7 SUMMARY:29th Annual International Prostate Cancer Update (IPCU) CREATED:20181113T173316Z DTSTAMP:20181113T173316Z URL:https://lugpa.org/events/international-prostate-cancer-update-ipcu/ DESCRIPTION:LUGPA is pleased to co-sponsor the 29th annual International Prostate Cancer Update (IPCU) with Grand Rounds in Urology™ in 2019. This CME-accredited conference is led by expert, international faculty focusing on prostate cancer treatment updates for urologists, medical oncologists, radiation oncologists, and other healthcare professionals.IPCU will feature a LUGPA lecture series focusing on topics specific to independent urology practices. Join LUGPA and Grand Rounds in Urology™ in January to gain exposure to a comprehensive review of treating prostate cancer patients and discuss the issues with peers and experts.\N  X-ALT-DESC;FMTTYPE=text/html:LUGPA is pleased to co-sponsor the 29th annual International Prostate Cancer Update (IPCU) with Grand Rounds in Urology™ in 2019. This CME-accredited conference is led by expert, international faculty focusing on prostate cancer treatment updates for urologists, medical oncologists, radiation oncologists, and other healthcare professionals.

IPCU will feature a LUGPA lecture series focusing on topics specific to independent urology practices. Join LUGPA and Grand Rounds in Urology™ in January to gain exposure to a comprehensive review of treating prostate cancer patients and discuss the issues with peers and experts.

 
LAST-MODIFIED:20181113T173954Z SEQUENCE:398 LOCATION: GEO:37.09024000;-95.71289100 X-LOCATION-DISPLAYNAME:The Westin Riverfront at Beaver Creek X-ACCESS:1 X-HITS:1694 X-COLOR:3366CC X-SHOW-END-TIME:1 END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20190829 DTEND;VALUE=DATE:20190901 UID:9D7AE654-C03A-43D9-AA97-90D2B2BB6D1C SUMMARY:Advanced Prostate Cancer Consensus Conference (APCCC 2019) CREATED:20180510T160858Z DTSTAMP:20180510T160858Z URL:https://www.apccc.org DESCRIPTION:The Advanced Prostate Cancer Consensus Conference (APCCC) was initiated to provide a forum to discuss and debate current questions on the clinical management of men with advanced prostate cancer, with a special focus on these unclear situations. Two days of the conference are dedicated to high-level presentations, discussions, and debates led by the panel of international and interdisciplinary prostate cancer experts to summarize and conceptualize the available literature and evidence.The conference provides an update on the current standard of advanced prostate cancer management with a focus on situations with no high-level evidence for a specific treatment option. It is entirely focused on “knowledge translation” by summarising and conceptualizing the current standards of advanced prostate cancer management and disseminating the results of the consensus discussions and votings. In addition, it culminates with an interdisciplinary expert consensus panel meeting that will discuss and vote on predefined questions relating to key areas where there is lack of evidence or conflict regarding the optimal treatment of men with advanced prostate cancer. Participants will be able to attend the two days of the discussions as well as the voting of the panelists as part of the conference, with the consensus summary being published after the meeting in a high impact medical journal.Location: Congress Center Basel, Basel, Switzerland2019 Program\NPreview of the APCCC 2019 - Interview with Silke GillessenSilke Gillessen, in conversation with Alicia Morgans, provides an overview of many of the changes we are experiencing in clinical practice since the 2017 APCCC. See APCCC 2017 Coverage X-ALT-DESC;FMTTYPE=text/html:The Advanced Prostate Cancer Consensus Conference (APCCC) was initiated to provide a forum to discuss and debate current questions on the clinical management of men with advanced prostate cancer, with a special focus on these unclear situations. Two days of the conference are dedicated to high-level presentations, discussions, and debates led by the panel of international and interdisciplinary prostate cancer experts to summarize and conceptualize the available literature and evidence.

The conference provides an update on the current standard of advanced prostate cancer management with a focus on situations with no high-level evidence for a specific treatment option. It is entirely focused on “knowledge translation” by summarising and conceptualizing the current standards of advanced prostate cancer management and disseminating the results of the consensus discussions and votings. In addition, it culminates with an interdisciplinary expert consensus panel meeting that will discuss and vote on predefined questions relating to key areas where there is lack of evidence or conflict regarding the optimal treatment of men with advanced prostate cancer. Participants will be able to attend the two days of the discussions as well as the voting of the panelists as part of the conference, with the consensus summary being published after the meeting in a high impact medical journal.

Location: Congress Center Basel, Basel, Switzerland

2019 Program

Preview of the APCCC 2019 - Interview with Silke Gillessen
Silke Gillessen, in conversation with Alicia Morgans, provides an overview of many of the changes we are experiencing in clinical practice since the 2017 APCCC. 

See APCCC 2017 Coverage
LAST-MODIFIED:20190731T162545Z SEQUENCE:38621807 X-ACCESS:1 X-HITS:5498 X-COLOR:3366CC X-SHOW-END-TIME:1 END:VEVENT END:VCALENDAR